An evaluation of the pharmacokinetic profile of VSLI (vincristine sulfate liposome injection, 0.16 mg/mL) in patients with malignant melanoma and hepatic dysfunction secondary to metastases
Latest Information Update: 07 Oct 2022
At a glance
- Drugs Vincristine (Primary)
- Indications Malignant melanoma
- Focus Pharmacokinetics
- Sponsors Spectrum Pharmaceuticals
- 04 Jan 2012 Primary endpoints identified as reported by ClinicalTrials.gov.
- 06 Dec 2007 Status changed from in progress to completed.
- 30 Oct 2007 Status changed from recruiting to in progress.